For those also interested in understanding different insulin options, discussing comprehensive metabolic management with your provider is helpful
Not discomfort a real reason you won't comply with weekly injections
The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study
#DDW2025 OBESITY AND IBD by @EdwardLoftus2 Obesity is a chronic inflammatory statue Adipose tissue is not biologically inert (TNFa, IL-6, IL-8, leptin, adiponectin) Postulated role in the pathogenesis of IBD Potential risk factor for adverse outcomes Trends in BMI among IBD patients at diagnosis in Olmsted County, Doubling of obesity rates in 20 years in CD and UC (Johnson AM JCC 2021 and J Clin Gastro 2024) Obese patients more likely to have a colonic phenotype
That refers to how well patients handle the drug a key metric in trials on medicines containing GLP-1s, which often bring gastrointestinal side effects
Table of Contents Commonly Used Injection Sites for Retatrutide Retatrutide is injected subcutaneously into the abdomen (at least 5 cm from the navel), the anterolateral mid-thigh, or the outer upper arm, with all site guidance governed by the clinical trial protocol
